Analysts expect Revolution Medicines, Inc. to report revenue of 21.14 M for Q3 26, against a range of 19.07 M to 23.21 M. The most recent reported quarter, Q2 26, came in at 0.00, a 100.0% miss against the 1.65 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 353,949.65 | 409,245.49 | 0.00 | 31.56 M | 1.65 M | 3.67 M | 2.65 M | 1.75 M | 23.21 M | 190.08 M | 226.63 M | 294.62 M | 247.97 M | 321.30 M | 550.64 M | 601.78 M | ||||||||||
| Low Estimate | 306,404.17 | 361,814.51 | 0.00 | 26.26 M | 1.50 M | 3.32 M | 2.34 M | 1.55 M | 19.07 M | 171.05 M | 209.64 M | 254.10 M | 206.63 M | 291.15 M | 468.02 M | 519.17 M | ||||||||||
| Consensus Estimate | 330,176.91 | 385,530.00 | 0.00 | 28.91 M | 1.57 M | 3.50 M | 2.49 M | 1.65 M | 21.14 M | 180.57 M | 218.14 M | 274.36 M | 227.30 M | 306.23 M | 509.33 M | 560.47 M |
Analysts expect Revolution Medicines, Inc. to report earnings per share of -2.25 for Q3 26, against a range of -2.41 to -2.09. The most recent reported quarter, Q2 26, came in at -3.06, a 55.3% miss against the -1.97 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.94 | -1.12 | -1.13 | -1.31 | -1.61 | -1.86 | -2.29 | -3.06 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.89 | -0.98 | -0.94 | -1.01 | -1.25 | -1.44 | -1.82 | -1.85 | -2.09 | -1.93 | -1.54 | -1.50 | -1.68 | -1.63 | -0.66 | -0.63 | ||||||||||
| Low Estimate | -0.97 | -1.12 | -1.10 | -1.17 | -1.49 | -1.64 | -2.04 | -2.09 | -2.41 | -2.07 | -1.80 | -1.72 | -1.82 | -1.91 | -0.74 | -0.71 | ||||||||||
| Consensus Estimate | -0.93 | -1.05 | -1.02 | -1.09 | -1.37 | -1.54 | -1.93 | -1.97 | -2.25 | -2.00 | -1.67 | -1.61 | -1.75 | -1.77 | -0.70 | -0.67 |
Pull Wall Street consensus for Revolution Medicines, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=RVMD&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "RVMD", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=RVMD&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();